Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms The Endurance 2 Trial
- 21 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 21 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated